CA2137342A1 - Test quantitatif pour la determination du temps de thrombine - Google Patents
Test quantitatif pour la determination du temps de thrombineInfo
- Publication number
- CA2137342A1 CA2137342A1 CA 2137342 CA2137342A CA2137342A1 CA 2137342 A1 CA2137342 A1 CA 2137342A1 CA 2137342 CA2137342 CA 2137342 CA 2137342 A CA2137342 A CA 2137342A CA 2137342 A1 CA2137342 A1 CA 2137342A1
- Authority
- CA
- Canada
- Prior art keywords
- thrombin
- fibrinogen
- plasma
- concentration
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000190 Thrombin Proteins 0.000 title claims abstract description 111
- 229960004072 thrombin Drugs 0.000 title claims abstract description 91
- 238000012360 testing method Methods 0.000 title abstract description 23
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 57
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 56
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 56
- 238000000034 method Methods 0.000 claims abstract description 39
- 239000003112 inhibitor Substances 0.000 claims abstract description 36
- 206010053567 Coagulopathies Diseases 0.000 claims abstract description 25
- 230000000694 effects Effects 0.000 claims abstract description 21
- 230000036470 plasma concentration Effects 0.000 claims abstract description 7
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 22
- 229920000669 heparin Polymers 0.000 claims description 22
- 229960002897 heparin Drugs 0.000 claims description 22
- 230000035602 clotting Effects 0.000 claims description 20
- 230000001225 therapeutic effect Effects 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 17
- 238000003556 assay Methods 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 229940106780 human fibrinogen Drugs 0.000 claims description 9
- 102000007327 Protamines Human genes 0.000 claims description 6
- 108010007568 Protamines Proteins 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000007865 diluting Methods 0.000 claims description 6
- 239000013610 patient sample Substances 0.000 claims description 6
- 239000000523 sample Substances 0.000 claims description 6
- 229950008679 protamine sulfate Drugs 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 238000013207 serial dilution Methods 0.000 claims description 4
- 230000003472 neutralizing effect Effects 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 claims description 3
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 2
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims 1
- 239000000376 reactant Substances 0.000 claims 1
- 238000010790 dilution Methods 0.000 abstract description 12
- 239000012895 dilution Substances 0.000 abstract description 12
- 230000015271 coagulation Effects 0.000 abstract description 7
- 238000005345 coagulation Methods 0.000 abstract description 7
- 238000004445 quantitative analysis Methods 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 description 82
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 54
- 230000002159 abnormal effect Effects 0.000 description 16
- 108010027612 Batroxobin Proteins 0.000 description 13
- 239000003146 anticoagulant agent Substances 0.000 description 13
- 108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 12
- 102000007625 Hirudins Human genes 0.000 description 12
- 108010007267 Hirudins Proteins 0.000 description 12
- 239000000208 fibrin degradation product Substances 0.000 description 12
- 229940006607 hirudin Drugs 0.000 description 12
- 229940127219 anticoagulant drug Drugs 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 108010007948 Abnormal Fibrinogens Proteins 0.000 description 4
- 102000007376 Abnormal Fibrinogens Human genes 0.000 description 4
- 108010080865 Factor XII Proteins 0.000 description 4
- 102000000429 Factor XII Human genes 0.000 description 4
- 230000010100 anticoagulation Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000002323 fibrinogen variant Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 206010047249 Venous thrombosis Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 208000015294 blood coagulation disease Diseases 0.000 description 3
- 208000027826 familial dysfibrinogenemia Diseases 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010003178 Arterial thrombosis Diseases 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 108010014173 Factor X Proteins 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000004019 antithrombin Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- KSEZPRJUTHMFGZ-UHFFFAOYSA-N 1-(3-ethyl-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)ethanone Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=O)C(CC)=C2 KSEZPRJUTHMFGZ-UHFFFAOYSA-N 0.000 description 1
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 241000237902 Hirudo medicinalis Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010051125 Hypofibrinogenaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 230000003024 amidolytic effect Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010058143 atroxin Proteins 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 208000023414 familial retinal arterial macroaneurysm Diseases 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003455 independent Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229940045627 porcine heparin Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960003766 thrombin (human) Drugs 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/815—Protease inhibitors from leeches, e.g. hirudin, eglin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/974—Thrombin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
- G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89363192A | 1992-06-05 | 1992-06-05 | |
US07/893,631 | 1993-02-22 | ||
US08/021,033 | 1993-02-22 | ||
US08/021,033 US5476771A (en) | 1993-02-22 | 1993-02-22 | Test for quantitative thrombin time |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2137342A1 true CA2137342A1 (fr) | 1993-12-23 |
Family
ID=26694177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA 2137342 Abandoned CA2137342A1 (fr) | 1992-06-05 | 1993-06-03 | Test quantitatif pour la determination du temps de thrombine |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0643727A4 (fr) |
JP (1) | JPH08501682A (fr) |
AU (2) | AU4405293A (fr) |
CA (1) | CA2137342A1 (fr) |
WO (2) | WO1993025220A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6221672B1 (en) | 1996-04-30 | 2001-04-24 | Medtronic, Inc. | Method for determining platelet inhibitor response |
DE29723808U1 (de) * | 1996-04-30 | 1999-11-04 | Medtronic, Inc., Minneapolis, Minn. | Vorrichtung zur Bestimmung der Blutplättcheninhibitor-Ansprechempfindlichkeit |
JP3626982B2 (ja) * | 1997-08-29 | 2005-03-09 | アークレイ株式会社 | タンパク質分解酵素阻害物質の測定方法およびそれに用いる測定キット |
CN103238070B (zh) * | 2010-10-01 | 2016-06-29 | 丹麦国家医院 | 能够调节/保护内皮完整性的用于预防或治疗急性创伤性凝血病和心脏骤停复苏的化合物 |
US20150057325A1 (en) * | 2012-03-30 | 2015-02-26 | Rigshospitalet | Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest |
CN117741166B (zh) * | 2024-02-19 | 2024-04-26 | 北京水木济衡生物技术有限公司 | 一种多项目复合凝血质控品及其制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4496653A (en) * | 1980-10-09 | 1985-01-29 | Boehringer Mannheim Gmbh | Process for the determination of antithrombin-BM |
DE3038163A1 (de) * | 1980-10-09 | 1982-05-06 | Boehringer Mannheim Gmbh, 6800 Mannheim | Thrombininhibitor, seine herstellung und verwendung |
DE3445532A1 (de) * | 1984-12-13 | 1986-06-19 | Plantorgan Werk Heinrich G.E. Christensen, KG, 2903 Bad Zwischenahn | Hirudin-pa, desulfatohirudine-pa, verfahren zur herstellung und pharmazeutische mittel, die diese wirkstoffe enthalten |
US5019393A (en) * | 1988-08-03 | 1991-05-28 | New England Deaconess Hospital Corporation | Biocompatible substance with thromboresistance |
US5196404B1 (en) * | 1989-08-18 | 1996-09-10 | Biogen Inc | Inhibitors of thrombin |
US4952562A (en) * | 1989-09-29 | 1990-08-28 | Rorer Pharmaceutical Corporation | Anti-thrombotic peptides and pseudopeptides |
EP0442843B1 (fr) * | 1990-02-14 | 1998-09-09 | Pentapharm A.G. | Inhibiteur pour le prétraitement anticoagulant des échantillons sanguins |
US5118790A (en) * | 1990-07-24 | 1992-06-02 | Sri International | Analogs of hirudin |
-
1993
- 1993-06-02 AU AU44052/93A patent/AU4405293A/en not_active Abandoned
- 1993-06-02 WO PCT/US1993/005297 patent/WO1993025220A1/fr active Application Filing
- 1993-06-03 EP EP93918119A patent/EP0643727A4/fr not_active Withdrawn
- 1993-06-03 WO PCT/US1993/005315 patent/WO1993025578A1/fr not_active Application Discontinuation
- 1993-06-03 AU AU47681/93A patent/AU4768193A/en not_active Abandoned
- 1993-06-03 CA CA 2137342 patent/CA2137342A1/fr not_active Abandoned
- 1993-06-03 JP JP6501586A patent/JPH08501682A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0643727A4 (fr) | 1998-05-13 |
AU4768193A (en) | 1994-01-04 |
WO1993025578A1 (fr) | 1993-12-23 |
WO1993025220A1 (fr) | 1993-12-23 |
EP0643727A1 (fr) | 1995-03-22 |
JPH08501682A (ja) | 1996-02-27 |
AU4405293A (en) | 1994-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Miletich et al. | Patients with Congenital Factor V Deficiency have Decreased Factor X a Binding Sites on their Platelets | |
Hersch et al. | The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor | |
d'Angelo et al. | Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. | |
US5525478A (en) | Soluble thrombomodulin-based one-stage assay for vitamin-K dependent coagulation-inhibiting proteins | |
US5906942A (en) | Method for preparing stable coagulation controls | |
US4234682A (en) | Method and reagent for determining biologically active heparin in plasma | |
Kirchhof et al. | The determination of prothrombin using synthetic chromogenic substrates; choice of a suitable activator | |
Kluft et al. | alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder. | |
US5726028A (en) | Method for detecting disturbances of the protein c/protein s system | |
EP0107383A1 (fr) | Réactif activé diagnostique pour thromboplastine partielle | |
US4948724A (en) | Composition, kit and method for assaying heparin and a method for making the composition | |
CA2137342A1 (fr) | Test quantitatif pour la determination du temps de thrombine | |
US5476771A (en) | Test for quantitative thrombin time | |
JPH06504682A (ja) | タンパクs発色原アッセイ | |
Weinstein et al. | Species specificity of the fibrinolytic effects of activated protein C | |
US5529905A (en) | Method of assaying plasma proteins with prothrombin fragments | |
EP0324027A1 (fr) | Analyses ameliorees d'activateur plasminogene et d'inhibiteur d'activateur plasminogene | |
Sala et al. | Dysfunctional activated protein C (PC Cadiz) in a patient with thrombotic disease | |
CA2039173C (fr) | Dosage chromogene du facteur ix | |
US4851336A (en) | Composition, kit, and method for assaying heparinano a method for making the composition | |
US5753510A (en) | Calibrator for use in test methods for detecting a defective coagulation factor V | |
EP0217768B1 (fr) | Méthode et composés pour la mise en évidence de l'héparine | |
Kandall et al. | Determinants of Prothrombinase Activity and Modification of Prothrombin Conversion by Thrombin‐Treated Factor V | |
van de Waart et al. | A functional test for protein S activity in plasma | |
Duncan et al. | A clinical evaluation of automated chromogenic tests as substitutes for conventional prothrombin time and activated partial thromboplastin time tests. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |